Gilotrif
Gilotrif ingredients
| Active ingredient | Strength |
|---|---|
| Afatinib | 30 mg/1, 20 mg/1, 40 mg/1 |
What Gilotrif is used for
The FDA lists the approved uses on the official label (below). In the EU, afatinib is approved as Giotrif for:
Giotrif as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Gilotrif
- Generic name
- Afatinib
- Made by
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA201292
- On the US market since
- 2013
Official information
- Gilotrif prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Afatinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Gilotrif?
Gilotrif (Afatinib) is a cancer medicine made by Boehringer Ingelheim Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Gilotrif?
Gilotrif contains Afatinib (30 mg/1, 20 mg/1, 40 mg/1).
Is Gilotrif approved in Europe?
The same active substance is approved in the EU as Giotrif.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA